Overview

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care alone.
Phase:
Phase 3
Details
Lead Sponsor:
Idorsia Pharmaceuticals Ltd.